Search clinical trials for: CLS001 (Omiganan)

Total 249 results

Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Sun Yat-sen University

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Massachusetts General Hospital
Gelesis, Inc.

Completed

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

Constipation | Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Institute of Liver and Biliary Sciences, India

Completed

To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure

Chronic Liver Failure

India
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Medullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine Carcinoma

China
Chimerix

Completed

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

CMV

United States, Belgium, Canada
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Maruho Co., Ltd.

Completed

A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

Cutaneous Warts

Netherlands
RemeGen Co., Ltd.

Not yet recruiting

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

China
Shanghai Zhongshan Hospital

Unknown

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Liver Transplantation | Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut

Advanced Melanoma

China
AnewPharma

Unknown

Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

Mucosal Melanoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer

Gastric Cancer | Locally Advanced Solid Tumor

China
Peking University
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Sellas Life Sciences Group
Sellas Life Sciences Group

Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Hematologic Malignancies

United States, China
AnewPharma

Unknown

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Zhongnan Hospital
Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
BGI, China
Fudan University; Shanghai 10th People's Hospital

Recruiting

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Sun Yat-sen University

Recruiting

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Alphamab Jilin Co., Ltd.

Unknown

Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women

Infertility, Female
Sun Yat-sen University

Recruiting

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation (BCIRT-01)

Muscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 Inhibitor

China
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
Peking University

Recruiting

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Cancer

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

China
AnewPharma

Unknown

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
Coherus Biosciences, Inc.

Not yet recruiting

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer (TRANSPARENT)

Nasopharyngeal Cancer Recurrent
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Carrick Therapeutics Limited

Completed

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Advanced Solid Malignancies

United States, United Kingdom
Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
Kavita Sarin
National Institutes of Health (NIH); Medivir; American Skin Association

Completed

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Skin Basal Cell Carcinoma

United States
Sun Yat-sen University

Recruiting

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma | Rituximab | Toripalimab

China
Peking University

Unknown

Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

Solid Tumor

China
N4 Pharma UK Ltd.
BDD Pharma Ltd

Completed

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

Erectile Dysfunction

United Kingdom
Mesoblast, Ltd.

Completed

Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

Osteoarthritis | Anterior Cruciate Ligament Injury

Australia

3

Subscribe